References
Alam, A., Jiang, L., Kittleson, G. A., Steadman, K. D., Nandi, S., Fuqua, J. L., … McDonald, K. A. (2018). Technoeconomic Modeling of Plant-Based Griffithsin Manufacturing. Frontiers in Bioengineering and Biotechnology , 6 , 102. https://doi.org/10.3389/fbioe.2018.00102
Alkanaimsh, S., Karuppanan, K., Guerrero, A., Tu, A., Hashimoto, B., Hwang, M. S., … McDonald, K. A. (2016). Transient expression of tetrameric recombinant human butyrylcholinesterase in Nicotiana benthamiana . Frontiers in Plant Science , 7 (June), 743. https://doi.org/10.3389/fpls.2016.00743
Almon, E., Khoury, T., Drori, A., Gingis-Velitski, S., Alon, S., Chertkoff, R., … Ilan, Y. (2017). An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. Journal of Immunological Methods , 446 , 21–29. https://doi.org/10.1016/J.JIM.2017.03.023
Aranha, H. (2011). Virus Safety Of Biopharmaceuticals. Retrieved from https://www.contractpharma.com/issues/2011-11/view_features/virus-safety-of-biopharmaceuticals
Ashani, Y. (2000). Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Development Research , 308 , 2000. https://doi.org/10.1002/1098-2299(200007/08)50:3/4<298::AID-DDR13>3.0.CO;2-X
Bremer, P. J., & Seale, R. B. (2010). Clean-in-Place (CIP). InEncyclopedia of Industrial Biotechnology . Hoboken, NJ, USA: John Wiley & Sons, Inc. https://doi.org/10.1002/9780470054581.eib231
Chisti, Y., & Moo-Young, M. (1994). Clean-in-place systems for industrial bioreactors: design, validation and operation . Journal of Industrial Microbiology (Vol. 3).
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., … Slebos, R. J. (2008). Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose- α-1,3-Galactose, 11 (358), 1109–1117. https://doi.org/10.1126/scisignal.2001449.Engineering
Corbin, J. M., Hashimoto, B. I., Karuppanan, K., Kyser, Z. R., Wu, L., Roberts, B. A., … Nandi, S. (2016). Semicontinuous Bioreactor Production of Recombinant Butyrylcholinesterase in Transgenic Rice Cell Suspension Cultures. Frontiers in Plant Science , 7 (March), 1–9. https://doi.org/10.3389/fpls.2016.00412
Corbin, J. M., Kailemia, M. J., Cadieux, C. L., Alkanaimsh, S., Karuppanan, K., Rodriguez, R. L., … Nandi, S. (2018). Purification, characterization, and N-glycosylation of recombinant butyrylcholinesterase from transgenic rice cell suspension cultures.Biotechnology and Bioengineering , 115 (5), 1301–1310. https://doi.org/10.1002/bit.26557
DARPA. (2012). Broad Agency Announcement Butyrylcholinesterase Expression in Plants DSO DARPA-BAA-12-31.
Geyer, B. C., Kannan, L., Cherni, I., Woods, R. R., Soreq, H., & Mor, T. S. (2010). Transgenic plants as a source for the bioscavenging enzyme, human butyrylcholinesterase. Plant Biotechnology Journal ,8 (8), 873–886. https://doi.org/10.1111/j.1467-7652.2010.00515.x
Grabowski, G. A., Golembo, M., & Shaaltiel, Y. (2014). Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology. Molecular Genetics and Metabolism , 112 (1), 1–8. https://doi.org/10.1016/j.ymgme.2014.02.011
Häkkinen, S. T., Reuter, L., Nuorti, N., Joensuu, J. J., Rischer, H., & Ritala, A. (2018). Tobacco BY-2 Media Component Optimization for a Cost-Efficient Recombinant Protein Production. Frontiers in Plant Science , 9 , 45. https://doi.org/10.3389/fpls.2018.00045
Harrison, R. G., Todd, P. W., Rudge, S. R., & Petrides, D. P. (2015).Bioseparations Science and Engineering . (K. E. Gubbins, M. A. Barteau, D. A. Lauffenburger, M. Morari, W. H. Ray, & W. B. Russel, Eds.) (2nd ed.). Oxford University Press.
Huang, T. K., & McDonald, K. A. (2012, March). Bioreactor systems for in vitro production of foreign proteins using plant cell cultures.Biotechnology Advances . https://doi.org/10.1016/j.biotechadv.2011.07.016
Jurchison, S. (2009). PharmAthene, Inc. Presents Phase I Clinical Trial Results and New Therapeutic Animal Model Data for Protexia(R) | BioSpace. Retrieved December 9, 2019, from https://www.biospace.com/article/releases/pharmathene-inc-presents-phase-i-clinical-trial-results-and-new-therapeutic-animal-model-data-for-protexia-r-/
Kelley, B. (2009). Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs , 1 (5), 443–452. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20065641
Kwon, J. Y., Jeong, S. H., Choi, J. W., Pak, Y. Y., & Kim, D. Il. (2013). Assessment of long-term cryopreservation for production of hCTLA4Ig in transgenic rice cell suspension cultures. Enzyme and Microbial Technology , 53 (3), 216–222. https://doi.org/10.1016/j.enzmictec.2013.05.008
Lydersen, B. K., D’Elia, N., & Nelson, K. L. (1994). Bioprocess engineering : systems, equipment and facilities . Wiley.
McNulty, M. J., Gleba, Y., Tusé, D., Hahn‐Löbmann, S., Giritch, A., Nandi, S., & McDonald, K. A. (2019). Techno‐economic analysis of a plant‐based platform for manufacturing antimicrobial proteins for food safety. Biotechnology Progress . https://doi.org/10.1002/btpr.2896
Miller, R. G., & Appel, S. H. (2017). Introduction to supplement: the current status of treatment for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration , 18 (sup1), 1–4. https://doi.org/10.1080/21678421.2017.1361447
Mir‐Artigues, P., Twyman, R. M., Alvarez, D., Cerda Bennasser, P., Balcells, M., Christou, P., & Capell, T. (2019). A simplified techno‐economic model for the molecular pharming of antibodies.Biotechnology and Bioengineering , 116 (10), 2526–2539. https://doi.org/10.1002/bit.27093
Mor, T. S. (2015). Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story. Biotechnology Letters ,37 (11), 2147–2150. https://doi.org/10.1007/s10529-015-1908-z
Mustafa, N. R., de Winter, W., van Iren, F., & Verpoorte, R. (2011). Initiation, growth and cryopreservation of plant cell suspension cultures. Nature Protocols , 6 (6), 715–742. https://doi.org/10.1038/nprot.2010.144
Nandi, S., Kwong, A. T., Holtz, B. R., Erwin, R. L., Marcel, S., & McDonald, K. A. (2016). Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. MAbs ,8 (8), 1456–1466. https://doi.org/10.1080/19420862.2016.1227901
Nandi, S., & McDonald, K. (2014). Expression of Recombinant Proteins in Plant Cell Culture. In K. Hefferon (Ed.), Plant-derived Pharmaceuticals: Principles and Applications for Developing Countries . CAB International. Retrieved from https://www.cabi.org/bookshop/book/9781780643434
Nandi, S., Yalda, D., Lu, S., Nikolov, Z., Misaki, R., Fujiyama, K., & Huang, N. (2005). Process development and economic evaluation of recombinant human lactoferrin expressed in rice grain. Transgenic Research , 14 (3), 237–249. https://doi.org/10.1007/s11248-004-8120-6
Petrides, D., Carmichael, D., Siletti, C., & Koulouris, A. (2014). Biopharmaceutical Process Optimization with Simulation and Scheduling Tools. Bioengineering , 1 , 154–187. https://doi.org/10.3390/bioengineering1040154
PharmAthene. (2015). United States Security and Exchange Commissions Form 10-K for the fiscal year ended December 31, 2014.
Ratner, M. (2010). Pfizer stakes a claim in plant cell-made biopharmaceuticals. Nature Biotechnology , 28 (2), 107–108. https://doi.org/10.1038/nbt0210-107
Rouf, S. ., Douglas, P. ., Moo-Young, M., & Scharer, J. . (2001). Computer simulation for large scale bioprocess design. Biochemical Engineering Journal , 8 (3), 229–234. https://doi.org/10.1016/S1369-703X(01)00112-7
Rouf, S. ., Moo-Young, M., Scharer, J. ., & Douglas, P. . (2000). Single versus multiple bioreactor scale-up: economy for high-value products. Biochemical Engineering Journal , 6 (1), 25–31. https://doi.org/10.1016/S1369-703X(00)00066-8
Rup, B., Alon, S., Amit-Cohen, B.-C., Almon, E. B., Chertkoff, R., Tekoah, Y., & Rudd, P. M. (2017). Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems —The taliglucerase alfa story. PloS One , 12 (10). https://doi.org/10.1371/journal.pone.0186211
Santos, R. B., Abranches, R., Fischer, R., Sack, M., & Holland, T. (2016). Putting the Spotlight Back on Plant Suspension Cultures.Frontiers in Plant Science , 7 (March), 1–12. https://doi.org/10.3389/fpls.2016.00297
Saxena, A., Tipparaju, P., Luo, C., & Doctor, B. P. (2010). Pilot-scale production of human serum butyrylcholinesterase suitable for use as a bioscavenger against nerve agent toxicity. Process Biochemistry ,45 (8), 1313–1318. https://doi.org/10.1016/j.procbio.2010.04.021
Schiffmann, R., Goker‐Alpan, O., Holida, M., Giraldo, P., Barisoni, L., Colvin, R. B., … Hughes, D. (2019). Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial. Journal of Inherited Metabolic Disease ,42 (3), jimd.12080. https://doi.org/10.1002/jimd.12080
Shaaltiel, Y., & Tekoah, Y. (2016). Plant specific N-glycans do not have proven adverse effects in humans. Nature Biotechnology ,34 (7), 706–708. https://doi.org/10.1038/nbt.3556
Stoller, J. K., & Aboussouan, L. S. (2009). Myths and misconceptions about α1-antitrypsin deficiency. Archives of Internal Medicine ,169 (6), 546–550.
Tabata, H. (2006). Production of Paclitaxel and the Related Taxanes by Cell Suspension Cultures of Taxus Species. Current Drug Targets . https://doi.org/http://dx.doi.org/10.2174/138945006776359368
Tekoah, Y., Shulman, A., Kizhner, T., Ruderfer, I., Fux, L., Nataf, Y., … Shaaltiel, Y. (2015). Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience. Plant Biotechnology Journal , 13 (8), 1199–1208. https://doi.org/10.1111/pbi.12428
Tusé, D., Tu, T., & McDonald, K. A. (2014). Manufacturing economics of plant-made biologics: Case studies in therapeutic and industrial enzymes. BioMed Research International , 2014 . https://doi.org/10.1155/2014/256135
Wilken, L. R., & Nikolov, Z. L. (2012). Recovery and purification of plant-made recombinant proteins. Biotechnology Advances ,30 (2), 419–433. https://doi.org/10.1016/j.biotechadv.2011.07.020
Xenopoulos, A. (2015). A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies. Journal of Biotechnology , 213 , 42–53. https://doi.org/10.1016/J.JBIOTEC.2015.04.020
Xu, S., Gavin, J., Jiang, R., & Chen, H. (2017). Bioreactor productivity and media cost comparison for different intensified cell culture processes. Biotechnology Progress , 33 (4), 867–878. https://doi.org/10.1002/btpr.2415